AC
JNCE

Ascend Capital’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Ascend Capital’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-180,629
Closed -$2.81M – 261
2017
Q3 		$2.81M Buy
+180,629
New +$2.55M 0.11% 129

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Ascend Capital's JNCE Position: Q4 2017 in Review

Ascend Capital sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2017, closing a stake of 180,629 shares — an estimated $2.81M sold.

Ascend Capital first reported a position in JNCE in Q3 2017 and held it in 1 quarter. The position peaked at $2.81M in Q3 2017. 83 funds tracked by Wall St. Rank hold JNCE as of Q4 2017.

  • Ascend Capital reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Ascend Capital sold 180,629 Jounce Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $2.81M.
  • Ascend Capital first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • Ascend Capital's Jounce Therapeutics, Inc. Common Stock position peaked at $2.81M in Q3 2017.
  • 83 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Ascend Capital's 13F filing for Q4 2017, filed 13 Feb 2018.